



04 March 2026  
EMA/52722/2026  
Human Medicines Division

## Overview of (invented) names reviewed in February 2026 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 24 March 2026

	NRG meeting 17-18 February		NRG meeting 15-16 April		NRG meeting 16-17 June		NRG meeting 22-23 September		NRG meeting 17-18 November		2026 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names	44	38									44	38
Proposed INN+MAH/TM names	2	0									2	0
Re-use/re-confirmation applications	2	0									2	0
Justification for retention of (invented) name *	3	4									3	4

\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 17-18 February		NRG meeting 15-16 April		NRG meeting 16-17 June		NRG meeting 22-23 September		NRG meeting 17-18 November		2026 total	
	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed
Total number of objections raised	77	150									77	150
Similarity with other (invented) name	50	133									50	133
Conveys misleading therapeutic connotations	0	0									0	0
Conveys misleading pharmaceutical connotations	0	0									0	0
Similarity with INN	6	2									6	2
Inclusion of INN stem	1	0									1	0
Unacceptable qualifiers	0	0									0	0
Conveys a promotional message	5	11									5	11
Appears offensive or has an inappropriate connotation	2	1									2	1
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0									0	0
Similarity between name of prodrug and related active substance	0	0									0	0
Inclusion of common umbrella segment	0	0									0	0
Potential difficulties in pronunciation	8	0									8	0
Others	5	1									5	1

See [Guideline on the acceptability of names for human medicinal products processed through the centralised procedure \(EMA/CHMP/287710/2014 - Rev. 7\)](#) for detailed explanations of criteria used.